Impact of coexistent adenomyosis on outcomes of patients with endometrioid endometrial cancer: a propensity score-matched analysis

Aydin HA, Hulya Ayik Aydin, Hülya Ayık Aydın, Tayfun Toptaş, Tayfun Toptas, Selen Bozkurt, Pestereli E, Elif Peştereli, Elif Pestereli, Simsek T, Tayup Simsek, Tayup Şimşek
Tumori · 2017 · vol. 104(1) , pp. 60–65 · doi:10.5301/tj.5000698 · PMID:29192745 · W2773300308
Observational OA: bronze CC0 ⤵ 7 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This propensity score-matched analysis found no significant differences in disease-free, overall, or disease-specific survival between endometrioid endometrial cancer patients with and without coexistent adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PURPOSE: Despite the common occurrence of adenomyosis in endometrial cancer (EC), there is a paucity and conflict in the literature regarding its impact on outcomes of patients. We sought to compare outcomes of patients with endometrioid type EC with or without adenomyosis. METHODS: A total of 314 patients were included in the analysis. Patients were divided into 2 groups according to the presence or absence of adenomyosis. Adenomyosis was identified in 79 patients (25.1%). A propensity score-matched comparison (1:1) was carried out to minimize selection biases. The propensity score was developed through multivariable logistic regression model including age, stage, and tumor grade as covariates. After performing propensity score matching, 70 patients from each group were successfully matched. Primary outcome of the study was disease-free survival (DFS), and the secondary outcomes were overall survival (OS) and disease-specific survival (DSS). RESULTS: Median follow-up time was 61 months for the adenomyosis positive group and 76 months for the adenomyosis negative group. There were no statistically significant differences in 3- and 5-year DFS, OS, and DSS rates between the 2 groups. Five-year DFS was 92% vs 88% (hazard ratio [HR] 1.54 [0.56-4.27]; p = 0.404), 5-year OS was 94% vs 92% (HR 1.60 [0.49-5.26]; p = 0.441), and 5-year DSS was 94% vs 96% (HR 2.51 [0.46-13.71]; p = 0.290) for patients with and without adenomyosis, respectively. CONCLUSIONS: Coexistent adenomyosis in EC is not a prognostic factor and does not impact survival outcomes.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Carcinoma, Endometrioid Endometrial Neoplasms Outcome Assessment, Health Care Adenomyosis Adenomyosis Adult Adult Aged Aged Aged, 80 and over Aged, 80 and over Carcinoma, Endometrioid Carcinoma, Endometrioid Carcinoma, Endometrioid Cohort Studies Cohort Studies Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (17)

Cited by (7)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:20:57.725456+00:00
License: CC0 · commercial use OK